Clinical Trials Logo

Solid Tumor clinical trials

View clinical trials related to Solid Tumor.

Filter by:
  • Suspended  
  • Page 1

NCT ID: NCT05708924 Suspended - Cancer Clinical Trials

MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Start date: April 28, 2023
Phase: Phase 1
Study type: Interventional

To determine the maximum tolerated dose (MTD) of FT538 monotherapy when administered via intraperitoneal (IP) catheter and in combination with intravenous (IV) enoblituzumab in patients with recurrent ovarian, fallopian tube, and primary peritoneal cancer.

NCT ID: NCT05338658 Suspended - Solid Tumor Clinical Trials

Study of PAT in Patients With Solid Tumor Cancers

Start date: May 19, 2023
Phase: Phase 1
Study type: Interventional

This is a single center Phase I study with extension of peptide alarm therapy (PAT) administered by intratumoral (IT) injection during the 1st course of a standard of care intravenous PD-1/PD-L1 inhibitor for the treatment of locally advanced or metastatic solid tumor cancers that has failed to be controlled after one or more prior therapies including a previous PD-1/PD-L1 inhibitor

NCT ID: NCT04276376 Suspended - Solid Tumor Clinical Trials

Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors

ARIANES
Start date: April 12, 2019
Phase: Phase 2
Study type: Interventional

The primary objective of the trial is to evaluate the antitumor activity of atezolizumab and rucaparib in patients with selected advanced solid tumors as measured by the Overall Response Rate

NCT ID: NCT03970382 Suspended - Solid Tumor Clinical Trials

A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors

Start date: July 3, 2019
Phase: Phase 1
Study type: Interventional

This is a first in human, single arm, open label, Phase 1a/1b study to determine the safety, feasibility, and efficacy of a single dose of NeoTCR-P1 T cells in participants with solid tumors.